Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Raises $10M in Sale of Convertible Note

NEW YORK (GenomeWeb News) – CombiMatrix said today that it has sold a $10 million secured convertible note to YA Global Investments.
The note is due on the earlier of July 10, 2010, or within four months after CombiMatrix receives payment from National Union Fire Insurance Company in accordance with a $35.7 million judgment issued by the United States District Court for the Central District of California.
CombiMatrix said that after covering costs, the net proceeds from the sale of the note were approximately $9.8 million, which will be used for working capital needs including “expansion” of its molecular diagnostics business.
"Though we can never predict a final outcome or timing, we hope this capital will bridge us to collection” of the judgment against National Union, Amit Kumar, president and CEO of CombiMatrix, said in a statement.
The note bears annual interest of 10 percent and is convertible into common stock of CombiMatrix at any time at a conversion price of $11.87 per share, which is equivalent to 842,460 shares, the company said.
CombiMatrix shares were priced at $10.97 in mid-afternoon Friday trade.
The note is secured by the $35.7 million judgment “as well as other assets of the company,” CombiMatrix said.
In addition to the note, CombiMatrix issued a warrant to YA to purchase 168,492 shares of common stock at an exercise price of $11.87, and a warrant to purchase 168,492 shares of common stock at an exercise price of $13.65.
The term of both warrants is five years, and CombiMatrix has the right to call the warrants upon meeting certain trading conditions.
As a condition to the financing, all executive officers of CombiMatrix, including the CEO and board of directors, have signed “lock-up agreements” that prohibit selling of their current or future holdings until one-half of the principal amount of the note has been converted or redeemed.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.